This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Multifocal Fibrosclerosis다초점 섬유경화증 (다초점섬유경화증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M35.5 | Special Copayment Reduction: V139 (rare disease Special Copayment Reduction)
B. SynonymsMultifocal fibrosclerosis, idiopathic retroperitoneal fibrosis, Ormond disease, IgG4-related fibrotic disease
C. Adult onsetLikelihood of first onset in adulthood: high (essentially an adult disease) — Mostly diagnosed in the 40s–60s, and pediatric onset is extremely rare. First onset of symptoms after middle adulthood is typical.
1. History1905: first description of retroperitoneal fibrosis by Ormond. 1960s: multifocal occurrence recognized. 1983: Comings et al. discussed reclassification as IgG4-associated systemic fibrosis. 2003: renewed attention with the introduction of the IgG4-related disease concept.
2. CausesCause unknown. May be included in the spectrum of IgG4-related disease. Drug-induced (methysergide, etc.). Autoimmune and inflammatory mechanisms. Rarely associated with malignancy.
3. GeneticsGenetic predisposition unknown. Some reports of association with HLA-DRB1*0301 and *1501. May share a genetic background with IgG4-related disease.
4. General epidemiologyExtremely rare. Retroperitoneal fibrosis is the most common form (about 1–2 per 100,000). Male predominance. Peak incidence in the 40s–60s. No accurate epidemiological statistics in Korea.
5. PathophysiologyFibrosis driven by TGF-β, IL-13, and IgG4-positive plasma cells. Immune responses to oxidized lipoproteins, TH2-skewed responses, and regulatory T cell abnormalities are the main candidate mechanisms.
6. SymptomsVaries by site of involvement: retroperitoneal fibrosis (low back pain, ureteral obstruction), sclerosing cholangitis (jaundice), sclerosing parathyroiditis, orbital pseudotumor, mediastinal fibrosis (cough, superior vena cava syndrome). Systemic symptoms are mild.
7. SignsObstructive findings by site of involvement. Hydronephrosis and renal failure with ureteral obstruction. Facial edema and dilated upper-limb veins with superior vena cava obstruction. Elevated ESR and CRP, elevated IgG4 (when IgG4-related), elevated serum creatinine.
8. ScreeningNo specific screening. Lesion sites identified by CT/MRI. Serum IgG4 measurement. Tissue biopsy for confirmation and exclusion of malignancy.
9. DiagnosisCT/MRI: lesions with fibrotic tissue characteristics. Elevated serum IgG4. Tissue biopsy: dense infiltration of IgG4+ plasma cells + fibrosis (when IgG4-related). Exclusion of malignancy, tuberculosis, and actinomycosis.
10. TreatmentSteroids (prednisolone 40–60 mg/day) are first-line. When IgG4-related, combination with rituximab or mycophenolate. Ureteral stents, surgical ureterolysis. Drug discontinuation when methysergide-induced.
11. PrognosisFavorable with early treatment. Irreversible damage from ureteral and biliary obstruction is the main cause of morbidity. IgG4-related forms respond well to steroids. Recurrence possible.
12. PreventionPrimary prevention not possible. Minimize exposure to causative drugs (methysergide, etc.). Early diagnosis and protection of renal function.
13. ReferencesVaglio A et al. Retroperitoneal fibrosis … and 9 other references

1. History

The history of multifocal fibrosclerosis begins with the first description of retroperitoneal fibrosis. It was not the French urologist Alban Ormond in 1905; in fact, in 1948 the American urologist John Kearney Ormond described cases in which the ureters were encased by idiopathic fibrous tissue, giving rise to the name 'Ormond's disease'. This report was the first systematic description of a disease in which fibrosis occurring behind the peritoneum (retroperitoneum) compresses the ureters, causing hydronephrosis and renal failure.

In the 1960s–70s, clinical observations began to accumulate that, in the same patient, fibrosis also occurs at other sites (mediastinum, thyroid, biliary tract, orbit, salivary glands, etc.) along with retroperitoneal fibrosis. In 1960, Halpern described the occurrence of retroperitoneal fibrosis, sclerosing cholangitis, and periarterial fibrosis around the carotid artery in the same patient, and subsequently the concept of 'multifocal fibrosclerosis' was proposed, and it began to be recognized as part of a systemic fibrotic disease rather than single-site involvement.

In 1983, Comings et al. suggested that multifocal fibrosclerosis may be due to an immune-mediated mechanism. In 2001, Hamano et al. in Japan reported that elevated IgG4 is observed in patients with autoimmune pancreatitis, and this discovery led to the recognition that a considerable portion of multifocal fibrosclerosis, including retroperitoneal fibrosis, is a phenotype of IgG4-related disease (IgG4-RD). Diagnostic criteria and classification were established at the 2011 International IgG4-RD Symposium, and as a result, distinguishing IgG4-RD-associated from non-associated forms of multifocal fibrosclerosis became clinically important.

In Korea, case reports of IgG4-related retroperitoneal fibrosis, sclerosing cholangitis, and the like have become active since the 2010s, and patient registration began with the application of rare disease Special Copayment Reduction (V139). Domestic epidemiological data are currently lacking, but the number of diagnoses is increasing with improved awareness.

2. Causes

The cause of multifocal fibrosclerosis has not yet been fully elucidated. According to current understanding, its pathogenesis is a complex interaction of genetic predisposition, immune dysregulation, and environmental triggers (drugs, infections, atherosclerosis-related antigens, etc.).

IgG4-related disease mechanism: A considerable portion of multifocal fibrosclerosis (especially retroperitoneal fibrosis, sclerosing cholangitis, and orbital pseudotumor) is being reclassified as part of IgG4-related disease (IgG4-RD). In IgG4-RD, IgG4-positive plasma cells and regulatory T cells heavily infiltrate the fibrotic tissue, and TH2/Treg cytokines such as TGF-β, IL-13, and IL-4 activate fibroblasts, inducing excessive collagen deposition. Serum IgG4 is often elevated to 135 mg/dL or more, but even in IgG4-RD, about 40% may have serum IgG4 within the normal range.

Atherosclerosis-related autoimmune mechanism: The formation of fibrotic tissue around the aorta and iliac arteries in idiopathic retroperitoneal fibrosis is explained by a mechanism in which an autoimmune response to oxidized low-density lipoprotein (ox-LDL) and ceruloplasmins within atherosclerotic plaques triggers fibrosis. This hypothesis is consistent with the detection of autoantibodies to ox-LDL in some patients.

Drug-induced: Methysergide (a migraine drug) has long been known as a classic drug cause of retroperitoneal fibrosis. Associations have also been reported with ergotamine, bromocriptine, cabergoline, beta-blockers, and others. In some cases, fibrosis improves with drug discontinuation.

3. Genetics

The genetic background of multifocal fibrosclerosis has been studied to a limited extent. Some associations with HLA genotypes have been reported: in idiopathic retroperitoneal fibrosis, HLA-DRB1*0301, HLA-DRB1*1501, and HLA-DQB1*0201 were observed at higher frequencies than in controls. This suggests that presentation of specific autoantigens via MHC II molecules contributes to disease onset.

GWAS studies of IgG4-related disease as a whole have reported associations with HLA-DRB1*0405, HLA-DQB1*0401, and others, and these genotypes were identified in East Asian, especially Japanese, IgG4-RD patients. The possibility that polymorphisms of immune regulation-related genes (IL-13, IL-4, CTLA-4, FOXP3) are associated with IgG4-RD susceptibility is being studied, but reproducible results have not yet been established. Familial occurrence of multifocal fibrosclerosis is extremely rare, so there appears to be no strong single-gene cause.

4. General epidemiology

Multifocal fibrosclerosis is a very rare disease worldwide. The prevalence of idiopathic retroperitoneal fibrosis, the most common form, is estimated at about 1–2 per 100,000 population, with an annual incidence of about 0.1–1 per 100,000. Involvement of other sites, such as sclerosing mediastinal fibrosis and the sclerosing cholangitis-associated form, is even rarer.

There is a male predominance (M:F = 2–3:1), and the median age of onset is about the 50s–60s. Pediatric onset is extremely rare. IgG4-related forms are reported at relatively high frequency in Asia (especially Japan), and there are reports that in Western countries too, about 30–50% of patients with retroperitoneal fibrosis meet IgG4-related criteria.

There are no accurate prevalence statistics in Korea, but a small number of patients have been identified through rare disease Special Copayment Reduction (V139) registration. Diagnostic delay is common (average 1–3 years), so the actual number of patients is estimated to be higher than the number registered. With recently improved physician awareness of IgG4-RD, patients diagnosed with retroperitoneal fibrosis, sclerosing cholangitis, and the like are being re-evaluated for IgG4-RD.

5. Pathophysiology

The core pathogenic mechanism of multifocal fibrosclerosis is a chronic fibrotic response driven by TGF-β and IL-13. In IgG4-related forms, massive infiltration of IgG4-positive plasma cells is characteristic, whereas in non-associated forms other immune cells predominate.

In the early stage, external antigens (oxidized LDL, infectious antigens, drug antigens, etc.) are processed by antigen-presenting cells (APCs), activating CD4+ T cells. In IgG4-RD, follicular helper T cells (Tfh) and regulatory T cells (Treg) in particular promote B cell class switching to the IgG4 subtype. The IgG4 molecule itself has weak complement activation and effector cell function, so it is understood to promote chronic inflammation and fibrosis rather than cause direct tissue damage.

TGF-β and IL-13 convert fibroblasts into myofibroblasts, increase collagen synthesis, and inhibit extracellular matrix degradation. As this process repeats, fibrotic tissue gradually accumulates and encases and compresses the related structures (ureters, bile ducts, blood vessels, etc.). At the same time, activated macrophages (M2 phenotype) secrete TGF-β and IL-10, further promoting fibrosis.

6. Symptoms

The symptoms of multifocal fibrosclerosis vary greatly depending on the site where fibrotic tissue develops, and multiple sites may be involved simultaneously or sequentially.

Retroperitoneal fibrosis: The most common form, with low back pain (buttock, groin, abdominal pain), fatigue, and weight loss as early symptoms. When the ureters are compressed, hydronephrosis and renal failure develop. Oliguria or anuria due to bilateral hydronephrosis may occur. On abdominal palpation, a hard mass around the abdominal aorta is sometimes felt.

Sclerosing mediastinal fibrosis: Superior vena cava syndrome (facial and upper-limb edema, headache, venous distension), cough, dyspnea, dysphagia, and chest pain develop. Recurrent pneumonia may occur with bronchial obstruction.

Sclerosing cholangitis and biliary fibrosis: Obstructive jaundice (yellowing of the eyes and skin), pruritus, right upper quadrant pain, and fever (with cholangitis) appear.

Riedel thyroiditis of the thyroid: The thyroid becomes stone-hard and swelling develops. Hypothyroidism, dyspnea due to airway compression, dysphagia, and voice changes may occur.

Orbital pseudotumor: Proptosis, eye pain, diplopia, and decreased vision appear.

7. Signs

The physical signs of multifocal fibrosclerosis vary with the site of involvement and are mostly secondary findings due to obstruction or compression.

Retroperitoneal fibrosis: An abdominal mass (hard periaortic mass) may be palpable on physical examination. Lower-limb edema (with venous or lymphatic obstruction). Elevated blood pressure (when the renal arteries are involved). Laboratory tests may show elevated serum creatinine, elevated ESR and CRP, anemia, and elevated serum IgG4.

Mediastinal fibrosis: Facial flushing and edema, dilated upper-limb veins, and jugular venous distension (JVD) are signs of superior vena cava syndrome. Chest CT or MRI shows a fibrotic mass in the mediastinum.

IgG4-related signs: Serum IgG4 elevated to 135 mg/dL or more. On histology, >10 IgG4-positive plasma cells per high-power field (HPF) and an IgG4/IgG ratio >40% are the histological criteria for IgG4-RD. With pancreatic involvement, findings of autoimmune pancreatitis may accompany it.

Imaging findings: Abdominal CT/MRI characteristically shows a fibrotic mass encasing the aorta and encasement of the ureters. T1 low signal and variable T2 signal (T2 high signal in the active phase, T2 low signal in the fibrotic phase) are seen. On PET-CT, active lesions show increased FDG uptake, which is useful for assessing treatment response and searching for multifocal lesions.

8. Screening

There is no general population screening test for multifocal fibrosclerosis. Clinically, situations in which this disease is suspected are mainly an incidentally discovered retroperitoneal mass, unexplained hydronephrosis, or systemic evaluation after diagnosis of IgG4-RD at another site.

Serum IgG4: When IgG4-RD is suspected, serum IgG4 measurement is the first-line screening test. A level of 135 mg/dL or more makes IgG4-RD likely, but a normal level does not exclude it (normal in ~40%). IgG4 may also be elevated in multiple myeloma, allergic diseases, parasitic infections, cancer, and others, so it cannot be diagnostic on its own.

CT/MRI: If retroperitoneal fibrosis is suspected, abdominal and pelvic CT or MRI is performed to evaluate the location of the fibrotic mass, ureteral compression, and the presence of hydronephrosis. Systemic evaluation including the chest and neck may be needed to search for multifocal involvement.

Whole-body FDG-PET-CT: Useful for assessing the extent of multifocal involvement and monitoring treatment response. FDG uptake is increased in active fibrotic lesions.

Tissue biopsy: Essential for excluding malignancy (lymphoma, retroperitoneal sarcoma, metastatic cancer) and confirming IgG4-RD. Performed by CT-guided core needle biopsy or surgical biopsy.

9. Diagnosis

Diagnosis of multifocal fibrosclerosis is based on a comprehensive evaluation of clinical, imaging, serum, and histological findings. Distinguishing IgG4-related from non-related forms is important.

IgG4-RD diagnostic criteria (2012 international pathology criteria): Confirmed when all of the following are met: ① swelling or mass of one or more organs on clinical and imaging evaluation, ② elevated serum IgG4 (>135 mg/dL), ③ infiltration of IgG4-positive plasma cells on histology (>10 per HPF) and IgG4/IgG ratio >40%. If only some criteria are met, it is classified as probable or possible.

Criteria specific to retroperitoneal fibrosis: Periaortic fibrotic mass + ureteral encasement on abdominal CT/MRI. Exclusion of malignancy, tuberculosis, actinomycosis, carcinoid tumor, and metastatic cancer. Confirmation of history of drugs such as methysergide.

Differential diagnosis: Retroperitoneal tumors (lymphoma, sarcoma), fibrosis of retroperitoneal lymph nodes after tuberculosis, actinomycosis, retroperitoneal metastasis of malignancy, systemic amyloidosis, sarcoidosis, carcinoid syndrome, methysergide-induced fibrosis, and others must be excluded.

Assessment of multifocal involvement: Once retroperitoneal fibrosis is confirmed, the biliary tract (MRCP), neck (MRI or ultrasound), mediastinum (chest CT), orbit (orbital MRI), pancreas (abdominal MRI, ERCP), and other sites are systematically evaluated to determine whether there is multifocal involvement. This is because multifocal involvement is common in IgG4-RD.

10. Treatment

Treatment of multifocal fibrosclerosis depends on whether it is IgG4-related and on the site of involvement. Corticosteroids are first-line treatment in most cases, aiming to prevent organ damage and restore function.

Corticosteroids: Start with prednisolone 40–60 mg/day and taper gradually as symptoms and imaging findings improve. In IgG4-RD-related forms, the response to steroids is good, with reduction in serum IgG4 and shrinkage of fibrotic tissue. Steroids also have some effect in non-IgG4-related forms. A total treatment duration of at least 1–2 years is recommended.

Rituximab: Very effective through B cell depletion in patients with relapsed or steroid-refractory IgG4-RD. Two intravenous doses of 1 g given 2 weeks apart is the standard schedule. Some studies have reported a clinical response rate of ~97%, and whether to give maintenance doses is individualized for each patient.

Mycophenolate mofetil, azathioprine: Used as maintenance therapy during steroid tapering or combined for the purpose of preventing relapse.

Surgical and endoscopic intervention: With ureteral obstruction, renal function is urgently protected with a ureteral stent or percutaneous nephrostomy. Afterwards, when fibrosis improves with steroid treatment, the stent is removed or surgical ureterolysis is performed. With biliary obstruction, endoscopic retrograde biliary drainage (ERCP + stent) is used to relieve jaundice.

Drug-induced forms: Discontinuation of the causative drug, such as methysergide, is essential, and in some cases improvement occurs with drug discontinuation alone.

11. Prognosis

The prognosis of multifocal fibrosclerosis varies greatly with early diagnosis and treatment. IgG4-related forms respond well to steroids and rituximab, and remission can be achieved after treatment, but relapse is common and irreversible fibrotic damage may remain.

Prognosis of retroperitoneal fibrosis: If hydronephrosis improves with early treatment, renal function can be preserved. If diagnosis is delayed and chronic renal failure is established, complete recovery of renal function is difficult. The goal is shrinkage of the fibrotic mass and relief of ureteral compression with steroid treatment.

Relapse: The relapse rate in IgG4-RD-associated retroperitoneal fibrosis is about 30–50%, and relapse is especially common during tapering after steroid monotherapy. There are reports that even after rituximab administration, long-term (2 years or more) maintenance of remission occurs in fewer than half.

Mortality: Direct death due to multifocal fibrosclerosis itself is rare. The main causes of morbidity and mortality are renal failure (ureteral obstruction), superior vena cava syndrome (mediastinal involvement), biliary sepsis (sclerosing cholangitis), and long-term adverse effects of steroids.

12. Prevention

Primary prevention of multifocal fibrosclerosis is not possible. In drug-induced forms (methysergide, etc.), avoiding use of the drug is a rare example of possible prevention. Prevention strategies focus on early diagnosis, protection of renal function, and monitoring for relapse.

In retroperitoneal fibrosis, early detection of hydronephrosis and renal failure due to ureteral compression is important. In adults with unexplained low back pain and decreased renal function, early identification of retroperitoneal lesions by abdominal CT is recommended. After IgG4-RD is confirmed, systemic evaluation for multifocal involvement and regular follow-up are essential for early detection of relapse and new organ involvement. During steroid treatment, osteoporosis prevention, blood glucose monitoring, and infection prevention are rigorously carried out.

13. References

  1. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367(9506):241-251. DOI: 10.1016/S0140-6736(06)68035-5. PMID: 16427494.
  2. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-551. DOI: 10.1056/NEJMra1104650. PMID: 22316447.
  3. Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688-1699. DOI: 10.1002/art.39132. PMID: 25809420.
  4. Wallwork R, Perugino CA, Fu X, et al. Rituximab for IgG4-related disease. Lancet Rheumatol. 2021;3(2):e106-e116. DOI: 10.1016/S2665-9913(20)30296-7. PMID: 33521704.
  5. Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol. 2010;34(12):1812-1819. DOI: 10.1097/PAS.0b013e3181f7266b. PMID: 21107087.
  6. Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology (Oxford). 2020;59(Suppl 3):iii123-iii131. DOI: 10.1093/rheumatology/keaa089. PMID: 32348491.
  7. Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing IgG4-related disease. Ann Rheum Dis. 2015;74(6):1161-1164. PMID: 25637002.
  8. Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982-984. PMID: 14614606.
  9. Carruthers MN, Khosroshahi A, Augustin T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis. 2015;74(1):14-18. PMID: 25015374.
  10. Cho S, Kim YJ, Lee SS, et al. IgG4-related retroperitoneal fibrosis presenting with bilateral hydronephrosis in Korean patients. Korean J Intern Med. 2019;34(4):927-933. DOI: 10.3904/kjim.2017.264. PMID: 29976052.